Systemic and tissue chamber fluid platinum concentrations released from cis-diamminedichloroplatinum II-impregnated polymethylmethacrylate in healthy dogs
Buss, M.S.; Henry, C.J.; Tyler, J.W.; Tobias, K.S.; Daoud, S.; Hoopes, J.; Moore, M.P.
American Journal of Veterinary Research 60(3): 280-283
1999
ISSN/ISBN: 0002-9645 PMID: 10188807 Document Number: 501358
cis-Diamminedichloroplatinum (cisplatin; 20 mg)-impregnated polymethylmethacrylate cylinders were placed in s.c. tissue chambers overlying the thorax (treated site) in 6 healthy dogs. An empty tissue chamber was placed over the opposite side (control site). Plasma platinum levels were measured before implantation, at 3, 6, and 12 h after implantation on day 0, and once daily on days 1, 2, 3, 7, 14, 21, and 29. Platinum levels were measured in tissue chamber fluid samples collected at the same times as blood samples. Complete blood count, serum urea nitrogen and creatinine concentration were measured, and urine samples were examined on days 1, 2, 3, 7, 14, 21, and 29. The dogs were examined PM at the end of the study. Tissue chamber platinum concentrations at the treated site were significantly greater than plasma and control site tissue chamber concentrations on days 2, 3, 7, 10. Mean plasma platinum concentration at 3 (0.735 micro g/ml), 6 (0.691 micro g/ml), 12 (0.534 micro g/ml), 24 (0.131 micro g/ml), 48 (0.2 micro g/ml), 72 (0.1 micro g/ml), and 158 (0.014 micro g/ml) h was significantly greater than pretreatment values (0.0 micro g/ml). Plasma platinum concentration 10 days after treatment (0.011 micro g/ml) did not significantly differ from pretreatment values. There were no local or systemic adverse reactions. The results show that this route of cisplatin administration was safe and that higher concentrations of platinum was released locally relative to plasma concentration for an extended period.